Bioavailability Study of Oral Minoxidil 1 mg in Androgenetic Alopecia: Randomized Crossover Trial in Healthy Volunteers Under Fasting Conditions

The primary objective of this study is to evaluate the **bioavailability** of oral **minoxidil** 1 mg in healthy volunteers. This is assessed after both single and multiple dose administrations under fasting conditions. Understanding the bioavailability of minoxidil is clinically relevant as it provides insights into the drug's absorption and systemic availability, which are crucial for optimizing therapeutic efficacy and safety in the treatment of **androgenetic alopecia**. No secondary objectives are specified for this trial.

The clinical trial focuses on **androgenetic alopecia** and involves a study population consisting exclusively of female participants. The age range of the participants is categorized as adults, specifically between 18 to 64 years. The trial does not include any vulnerable populations. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. The selection criteria for the trial population, including any key inclusion or exclusion criteria, have not been disclosed by the sponsor.

The clinical trial is designed as a **randomized**, crossover bioavailability study to evaluate the effects of oral minoxidil 1 mg in healthy volunteers. The trial will assess the bioavailability of the drug after both single and multiple dose administrations under fasting conditions. The study is conducted in a **double-blind** manner to ensure unbiased results, with a control group receiving a placebo. The trial is categorized as a Phase 3 study, focusing on the medical condition **androgenetic alopecia**.

The trial is expected to commence recruitment on September 15, 2023, and is estimated to conclude by November 9, 2023. Participants will be involved in the study for the duration of the trial, which includes several key visits. The initial visit, known as the inclusion or screening visit, will determine eligibility based on predefined criteria. Following successful screening, participants will undergo a series of follow-up visits to monitor drug effects and collect necessary data. The end-of-study visit will conclude the participant's involvement, ensuring all data is collected and any final assessments are completed.

Participant involvement is expected to last throughout the trial period, with specific conditions outlined for early termination. These conditions may include adverse reactions, non-compliance with study protocols, or withdrawal of consent. The study aims to maintain rigorous adherence to protocol to ensure the integrity and reliability of the data collected. The trial's design and procedures are structured to provide comprehensive insights into the bioavailability of oral minoxidil, contributing valuable information to the treatment of androgenetic alopecia.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on September 15, 2023, with an estimated end date of November 9, 2023. The efficacy assessment will be conducted using predefined endpoints, although specific parameters or endpoints are not detailed in the provided data. The trial will follow a structured methodology to ensure the collection and analysis of efficacy data is consistent with clinical trial standards. The trial phase indicates a focus on evaluating the treatment's effectiveness and safety in a larger patient population. The absence of specific endpoints or measurement tools in the data suggests that these details will be defined in the full trial protocol. The trial's design will adhere to regulatory requirements to ensure the reliability and validity of the efficacy outcomes.